RNXT
RenovoRx, Inc.
Key Financials
Revenue
$1.1M
↑ 2511.6%
Operating Income
$-12510000
↓ 14.0%
Net Income
$-11168000
↓ 26.7%
Gross Profit
$796000
↑ 1751.2%
EPS (Diluted)
$-0.32
↑ 20.0%
Shareholders' Equity
$5.4M
↑ 21.1%
Total Liabilities
$2.7M
↓ 26.6%
Total Assets
$8.1M
↓ 0.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/13/2026 | View on SEC |
| 8-K/A | 8/13/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| 8-K | 8/4/2026 | View on SEC |
| 8-K | 7/2/2026 | View on SEC |
| S-8 | 6/30/2026 | View on SEC |
| 8-K | 6/30/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
| 10-K/A | 5/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RNXT |
| Company Name | RenovoRx, Inc. |
| CIK | 1574094 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 408-800-2649 |